PhD Program
Scientists and Projects
Departments and Host Institutions
Application Procedures
Search
Scientists and Projects
Sergio Abrignani
Silvia Barabino
Giorgio Battaglia
Andrea Becchetti
Ettore Biagi
Giorgio Biasi
Andrea Biondi
Francesco Broccolo
Silvia Brunelli
Maurizio C. Capogrossi
Giorgio Cattoretti
Guido Cavaletti
Clementina Cocuzza
Marco Crimi
Carlo Ferrarese
Giuliana Ferrari
Alessandra Ferri
Gaetano Finocchiaro
Katharina Fleischhauer
Maria Foti
Alberto Froio
Carlo Gambacorti-Passerini
Paolo Ghia
Gabriella Giagnoni
Roberto Giovannoni
Josée Golay
Francesca Granucci
Martino Introna
Marialuisa Lavitrano
Marzia Maria Lecchi
Renato Mantegazza
Massimo Masserini
Raffaela Meneveri
Paolo Mingazzini
Giuseppe Miserocchi
Monica Moro
Rosario Musumeci
Silvia Kirsten Nicolis
Sergio Ottolenghi
Gianfranco Parati
Marco Parenti
Roberto A. Perego
Maurizio Pesce
Antonio Pesenti
Alberto Piperno
Giulio Pompilio
Maria Pia Protti
Eva Reali
Paola Ricciardi-Castagnoli
Ilaria Rivolta
Antonella Ronchi
Elena Irene Rugarli
Giulio Alfredo Sancini
Valeria Tiranti
Antonio Torsello
Angelo Vescovi
Ivan Zanoni
Antonio Zaza
Massimo Zeviani
Name: Monica Moro
E-mail: moro@ingm.it
Department: National Institute of Molecular Genetics (INGM), Milan, Italy
Research Area(s): Cell-therapy in cancer

Research Projects

Identifcation of new functional markers of hematopoietic stem cells

We are generating  a library of about 2000 mouse polyclonal antisera specific for most human proteins that are on the cell mebrane or outside the cell and whose function is poorly known. The immunoproteomics platform we have set up has essentially moved towards the following points:

  • In silico prediction of all human genes (about 3000) with unknown function and possible expression on the cell surface or ouaside the cell (secreted).
  • Cloning and expression of these genes in bacteria (approx. 70-80% of the initial genes are successfully expressed and purified)
  • Purification of the recombinant proteins, immunisation of mice  and production of specific polyclonal antisera. The library of antisera will be used to identify and characterize new lineage markers for haematopoietic stem cells (from cord blood) subpopulation with specific commitment.

    Study of the ontogenesis of the immune system in patients whose immune system is reconsituted with cord blood trasplantation

    Allogeneic bone marrow transplantation  offers the potential for curing a variety of high risk hematological diseases. However lack of suitable donors is one of the major limitation to successful transplantation. To expand the donor pool, unrelated umbilical cord blood (UCB) has been investigated as an alternative source of  haematopoietic stem cells. In spite of the advantages, the clinical use of UCB transplantation, especially in adults, is still limited by the low dose of haematopoietic precursors in in a single UCB unit. Cotransplantation of two partially HLA-matched UCB units is a strategy to overcome the limitation of low cell dose.  We are interested in the accurate characterization of the innate and adaptive immune-system reconstitution in patients undergoing double UCB transplantation.

  • © 2003-2007 dimet.org
    Site created by ScienceDev and based on Easy Manager